What's Happening?
Researchers at the Gladstone Institutes have discovered that metformin, a common diabetes medication, may help keep HIV dormant after treatment cessation. The study, published in Immunity, highlights that metformin can activate mechanisms within infected
cells that maintain the virus in a dormant state. This finding is significant as it offers a potential pathway to control HIV without continuous antiretroviral therapy (ART). The research also identified two genes, DDIT4 and ZNF254, that act as protective locks to keep HIV inactive. The study involved analyzing blood samples from participants who paused ART under medical supervision, revealing that certain immune cells and gene expressions are linked to delayed viral rebound.
Why It's Important?
The potential use of metformin to delay or prevent HIV rebound is a promising development in the fight against HIV/AIDS. This approach could reduce the need for lifelong ART, which is essential for millions of people living with HIV. By keeping the virus dormant, metformin could improve the quality of life for patients and reduce the risk of developing AIDS. Additionally, the discovery of genes that help suppress HIV activity opens new avenues for therapeutic strategies, such as the 'block and lock' approach, which aims to permanently block HIV activation. This research could lead to more sustainable and less burdensome treatment options for HIV patients.
What's Next?
The research team plans to conduct preclinical and clinical studies to further explore the benefits of metformin in controlling HIV. These studies will test the drug's ability to maintain HIV in a dormant state and its potential to be part of a 'block and lock' strategy. If successful, this could lead to new treatment protocols that reduce the dependency on ART. The findings also suggest that enhancing the expression of genes like ZNF254 could be a future therapeutic target, potentially turning more patients into 'elite controllers' who naturally suppress the virus without treatment.
